NO820683L - Fremgangsmaate for fremstilling av antitumor-midler. - Google Patents
Fremgangsmaate for fremstilling av antitumor-midler.Info
- Publication number
- NO820683L NO820683L NO820683A NO820683A NO820683L NO 820683 L NO820683 L NO 820683L NO 820683 A NO820683 A NO 820683A NO 820683 A NO820683 A NO 820683A NO 820683 L NO820683 L NO 820683L
- Authority
- NO
- Norway
- Prior art keywords
- cysteine
- glyoxal
- aldehydes
- adducts
- tumor
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 8
- 238000004519 manufacturing process Methods 0.000 title description 2
- 239000002246 antineoplastic agent Substances 0.000 title 1
- LEQAOMBKQFMDFZ-UHFFFAOYSA-N glyoxal Chemical compound O=CC=O LEQAOMBKQFMDFZ-UHFFFAOYSA-N 0.000 claims description 42
- 229940015043 glyoxal Drugs 0.000 claims description 21
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 18
- 235000018417 cysteine Nutrition 0.000 claims description 18
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 11
- 239000007864 aqueous solution Substances 0.000 claims description 9
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 5
- 239000001301 oxygen Substances 0.000 claims description 4
- 229910052760 oxygen Inorganic materials 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 description 41
- 150000001299 aldehydes Chemical class 0.000 description 26
- AIJULSRZWUXGPQ-UHFFFAOYSA-N Methylglyoxal Chemical compound CC(=O)C=O AIJULSRZWUXGPQ-UHFFFAOYSA-N 0.000 description 18
- 201000011510 cancer Diseases 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 12
- 150000001875 compounds Chemical class 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 235000018102 proteins Nutrition 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 230000032823 cell division Effects 0.000 description 5
- 229920006395 saturated elastomer Polymers 0.000 description 5
- 231100000419 toxicity Toxicity 0.000 description 5
- 230000001988 toxicity Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 206010003445 Ascites Diseases 0.000 description 4
- 208000006552 Lewis Lung Carcinoma Diseases 0.000 description 4
- 125000003277 amino group Chemical group 0.000 description 4
- 230000000259 anti-tumor effect Effects 0.000 description 4
- 208000032839 leukemia Diseases 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- OFWXLYPSGLVHNC-NSCUHMNNSA-N (e)-4-hydroxypent-2-enal Chemical compound CC(O)\C=C\C=O OFWXLYPSGLVHNC-NSCUHMNNSA-N 0.000 description 3
- 229930189936 Glyoxalase Natural products 0.000 description 3
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 208000003747 lymphoid leukemia Diseases 0.000 description 3
- -1 methylgyoxal Chemical class 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- HGINCPLSRVDWNT-UHFFFAOYSA-N Acrolein Chemical compound C=CC=O HGINCPLSRVDWNT-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108010024636 Glutathione Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 239000002262 Schiff base Substances 0.000 description 2
- 150000004753 Schiff bases Chemical class 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 230000003327 cancerostatic effect Effects 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 230000001085 cytostatic effect Effects 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 231100000053 low toxicity Toxicity 0.000 description 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- 101100005765 Arabidopsis thaliana CDF1 gene Proteins 0.000 description 1
- 101100007579 Arabidopsis thaliana CPP1 gene Proteins 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 229930182843 D-Lactic acid Natural products 0.000 description 1
- JVTAAEKCZFNVCJ-UWTATZPHSA-N D-lactic acid Chemical compound C[C@@H](O)C(O)=O JVTAAEKCZFNVCJ-UWTATZPHSA-N 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- ZNZYKNKBJPZETN-WELNAUFTSA-N Dialdehyde 11678 Chemical compound N1C2=CC=CC=C2C2=C1[C@H](C[C@H](/C(=C/O)C(=O)OC)[C@@H](C=C)C=O)NCC2 ZNZYKNKBJPZETN-WELNAUFTSA-N 0.000 description 1
- 101100114828 Drosophila melanogaster Orai gene Proteins 0.000 description 1
- 238000004435 EPR spectroscopy Methods 0.000 description 1
- 208000003468 Ehrlich Tumor Carcinoma Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical group OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000000370 acceptor Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 125000003172 aldehyde group Chemical group 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- MLUCVPSAIODCQM-NSCUHMNNSA-N crotonaldehyde Chemical compound C\C=C\C=O MLUCVPSAIODCQM-NSCUHMNNSA-N 0.000 description 1
- MLUCVPSAIODCQM-UHFFFAOYSA-N crotonaldehyde Natural products CC=CC=O MLUCVPSAIODCQM-UHFFFAOYSA-N 0.000 description 1
- 150000001944 cysteine derivatives Chemical class 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 229940022769 d- lactic acid Drugs 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 125000005594 diketone group Chemical group 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 230000034659 glycolysis Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000005283 ground state Effects 0.000 description 1
- ZRALSGWEFCBTJO-UHFFFAOYSA-N guanidine group Chemical group NC(=N)N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 235000021395 porridge Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000006916 protein interaction Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000031539 regulation of cell division Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical compound [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C47/00—Compounds having —CHO groups
- C07C47/02—Saturated compounds having —CHO groups bound to acyclic carbon atoms or to hydrogen
- C07C47/12—Saturated compounds having —CHO groups bound to acyclic carbon atoms or to hydrogen containing more than one —CHO group
- C07C47/127—Glyoxal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24099281A | 1981-03-05 | 1981-03-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO820683L true NO820683L (no) | 1982-09-06 |
Family
ID=22908776
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO820683A NO820683L (no) | 1981-03-05 | 1982-03-04 | Fremgangsmaate for fremstilling av antitumor-midler. |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP0060659A1 (da) |
| JP (1) | JPS57167960A (da) |
| AU (1) | AU8048882A (da) |
| DK (1) | DK94182A (da) |
| NO (1) | NO820683L (da) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8424957D0 (en) * | 1984-10-03 | 1984-11-07 | Smith & Nephew Ass | Pharmaceutical compositions |
| EP1557537B1 (en) | 2002-10-29 | 2011-11-23 | Kabushiki Kaisha Toshiba | Steam valve |
-
1982
- 1982-02-15 AU AU80488/82A patent/AU8048882A/en not_active Abandoned
- 1982-03-04 DK DK94182A patent/DK94182A/da not_active Application Discontinuation
- 1982-03-04 NO NO820683A patent/NO820683L/no unknown
- 1982-03-05 EP EP82301132A patent/EP0060659A1/en not_active Withdrawn
- 1982-03-05 JP JP57035021A patent/JPS57167960A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP0060659A1 (en) | 1982-09-22 |
| AU8048882A (en) | 1982-09-09 |
| JPS57167960A (en) | 1982-10-16 |
| DK94182A (da) | 1982-09-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7223402B2 (en) | Method to prepare compositions comprising yeast treated with electromagnetic energy | |
| TW589187B (en) | Carbohydrate synthesis | |
| US10575537B2 (en) | Saury Maillard peptide and its preparation method and application | |
| CN102058888A (zh) | 一种治疗能量代谢异常的药物组合物和其应用 | |
| JPH08501275A (ja) | 腫瘍の治療のための製薬学的製品とそれの製造方法 | |
| CN105377271A (zh) | 含硒组合物及其治疗和预防与线粒体功能障碍有关的疾病或病症的应用 | |
| KR20190122453A (ko) | 진세노사이드 Re를 함유하는 호흡기 질환 예방 또는 치료용 약학적 조성물 | |
| JPH03501126A (ja) | アルコールへの病理学的渇望の発達を抑制する組成物 | |
| CN101370783B (zh) | 9-氧代吖啶-10-乙酸和1-烷基氨基-1-脱氧多羟基化合物的盐和混合物、包含其的药物组合物以及治疗方法 | |
| Musumeci et al. | Iron excretion in iron dextran-overloaded mice | |
| Együd | Studies on autobiotics: chemical nature of retine. | |
| US20240033234A1 (en) | Therapeutic compounds, formulations, and use thereof | |
| NO820683L (no) | Fremgangsmaate for fremstilling av antitumor-midler. | |
| KOTAKE | Xanthurenic acid, an abnormal metabolite of tryptophan and the diabetic symptoms caused in albino rats by its production | |
| US20160346320A1 (en) | Substance for inhibiting tissue calcification, tissue fibrosation and age-related diseases | |
| KR101247802B1 (ko) | 피페린 또는 이의 약학적으로 허용가능한 염을 유효성분으로 포함하는 염증성 질환 예방 및 치료용 조성물 | |
| RU2427373C1 (ru) | Средство для индукции эндогенного интерферона | |
| Lilja | Cerebro-cortical nekros (CCN) hos kalv. En experimentell reproduktion av lidandet: An Experimental Reproduction of the Disease | |
| TW406080B (en) | Micacocidin derivatives | |
| Hickman et al. | The effect of carbohydrate on δ-aminolaevulinate synthetase: The role of ribonucleic acid | |
| US10307424B2 (en) | Drug with hepatoprotective activity | |
| US9526717B2 (en) | Composition for treating immune diseases containing daurinol compound as active ingredient | |
| US20240197722A1 (en) | Anticancer composition inducing cell senescence and cell death | |
| CN107857754B (zh) | 一种化合物及其在制备预防/治疗类风湿性关节炎药物中的应用 | |
| JP2018083790A (ja) | オートファジー誘導剤 |